TranS1 (BAXSQ) Stock Price, News & Analysis

Company Overview

TranS1, Inc. was a medical device company focused on developing and commercializing minimally invasive technologies for spinal surgery. Its products were designed to provide alternatives to conventional open procedures and to support the treatment of spinal disorders.

The company’s principal product was the AxiaLIF system, a minimally invasive device and surgical approach used in certain lumbar spinal fusion procedures. TranS1 also developed products intended to assist surgeons with posterior spinal decompression and other spine-related procedures.

TranS1 later changed its name to Baxano Surgical, Inc. The company’s securities subsequently traded under the symbol BAXSQ, reflecting its status in bankruptcy proceedings. Available historical information indicates that its business was primarily directed at the U.S. spine-care and medical-device markets.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Industrials
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:BAXSQ
• Previous Symbol: NASDAQ:BAXS
• CIK: N/A
• Web: baxanosurgical.com
• Phone: +1-919-8000020
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A